Syncom Formulations Appoints Ankit Kedarmal Bankda as Chairman & Whole Time Director
Change in leadership can have a moderate impact on the company's strategy and performance.
Appointment of a new Chairman and Whole Time Director is generally perceived positively.
* Ankit Kedarmal Bankda (DIN: 02359461) has been appointed as a Director and designated as the Chairman and Whole Time Director of Syncom Formulations (India) Limited, effective from 9 August 2025. * The appointment was approved by the members of the company at the 37th Annual General Meeting held on Monday, 29 September 2025. * Ankit Kedarmal Bankda is a Post-Graduate in Commerce with 12 years of experience in manufacturing, finance, and administration. * He is the son of Shri Kedarmal Shankarlal Bankda, the Ex-Chairman and Whole Time Director of the company.
What to do with a filing like this
Syncom Formulations (India) Limited filed this with the NSE as a statutory disclosure, categorised under board changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Syncom Formulations (India) Limited. Read the original for the full detail.